{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:25:50Z","timestamp":1773033950420,"version":"3.50.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Unirradiated patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) who undergo anti-CD19 chimeric antigen receptor T-cell therapy (CART) have a predominant localized pattern of relapse, the significance of which is heightened in individuals with limited\/localized disease before CART. This study reports on the outcomes of patients with R\/R NHL and limited (&amp;lt;5 involved sites) disease bridged with or without radiotherapy. A multicenter retrospective review of 150 patients with R\/R NHL who received CART with &amp;lt;5 disease sites before leukapheresis was performed. Bridging treatment, if any, was administered between leukapheresis and CART infusion. Study end points included relapse-free survival (RFS), event-free survival (EFS), and overall survival. Before CART infusion, 48 patients (32%) received bridging radiotherapy (BRT), and 102 (68%) did not. The median follow-up was 21\u00a0months. After CART infusion, BRT patients had higher objective response (92% vs 78%; P\u00a0=\u00a0.046) and sustained complete response rates (54% vs 33%; P\u00a0=\u00a0.015). Local relapse in sites present before CART was lower in the BRT group (21% vs 46%; P\u00a0=\u00a0.003). BRT patients had improved 2-year RFS (53% vs 44%; P\u00a0=\u00a0.023) and 2-year EFS (37% vs 34%; P\u00a0=\u00a0.039) compared with patients who did not receive BRT. The impact of BRT was most prominent in patients who had \u22642 pre-CART involved disease sites, with 2-year RFS of 62% in patients who received BRT compared with 42% in those who did not (P\u00a0=\u00a0.002). BRT before CART for patients with limited (&amp;lt;5 involved disease sites) R\/R NHL improves response rate, local control, RFS, and EFS without causing significant toxicities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013647","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T20:11:10Z","timestamp":1721419870000},"page":"4877-4885","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of patients with R\/R B-cell NHL and limited (&amp;lt;5 sites) pre-CART disease bridged with or without radiotherapy"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9400-4771","authenticated-orcid":false,"given":"Omran","family":"Saifi","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Rule","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Stish","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"6Division of Experimental Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-098X","authenticated-orcid":false,"given":"Radhika","family":"Bansal","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Hathcock","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"7Department of Biostatistics, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-0809","authenticated-orcid":false,"given":"Jose C.","family":"Villasboas","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad","family":"Alhaj Moustafa","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-4248","authenticated-orcid":false,"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-5418","authenticated-orcid":false,"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-1504","authenticated-orcid":false,"given":"Jennifer L.","family":"Peterson","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"26","key":"2024092413262663100_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2024092413262663100_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"2024092413262663100_bib3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024092413262663100_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024092413262663100_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024092413262663100_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.beha.2018.07.011","article-title":"The promise of CAR T-cell therapy in aggressive B-cell lymphoma","volume":"31","author":"Nair","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"2024092413262663100_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"issue":"5","key":"2024092413262663100_bib8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2024092413262663100_bib9","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2024092413262663100_bib10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2005.09.030","article-title":"Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma","volume":"64","author":"Martens","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2024092413262663100_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","article-title":"Don't put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"116","author":"Saifi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 16","key":"2024092413262663100_bib12","article-title":"In-field recurrences in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART)","volume":"40","author":"Saifi","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024092413262663100_bib13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2024092413262663100_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"2024092413262663100_bib15","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2024092413262663100_bib16","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.ijrobp.2021.07.296","article-title":"Radiotherapy bridging in patients with R\/R high-grade lymphoma receiving CD19 CAR-T in the UK","volume":"111","author":"Kuhnl","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024092413262663100_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","article-title":"Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma","volume":"177","author":"Yu","year":"2022","journal-title":"Radiother Oncol"},{"issue":"1","key":"2024092413262663100_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.14338\/IJPT-20-00004.1","article-title":"Proton therapy as a bridging treatment in CAR T-cell therapy for relapsed and refractory large B-cell lymphoma: is there a role?","volume":"7","author":"Saifi","year":"2020","journal-title":"Int J Part Ther"},{"issue":"3","key":"2024092413262663100_bib19","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.ijrobp.2021.07.299","article-title":"Radiation therapy as bridging treatment to CAR T cell therapy in non-Hodgkin lymphoma","volume":"111","author":"Saifi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2024092413262663100_bib20","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.3324\/haematol.2023.283311","article-title":"Consolidative radiotherapy for residual fluorodeoxyglucose activity on day\u00a0+30 post CAR T-cell therapy in non-Hodgkin lymphoma","volume":"108","author":"Saifi","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"2024092413262663100_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamaoncol.2024.1113","article-title":"Comprehensive bridging radiotherapy for limited pre-CART non-Hodgkin lymphoma","volume":"10","author":"Saifi","year":"2024","journal-title":"JAMA Oncol"},{"issue":"24","key":"2024092413262663100_bib22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024092413262663100_bib23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2024092413262663100_bib24","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity","volume":"26","author":"Hoppe","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024092413262663100_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2024092413262663100_bib26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024092413262663100_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024092413262663100_bib28","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"2024092413262663100_bib29","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2024092413262663100_bib30","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024092413262663100_bib31","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive B cell lymphomas piror to chimeric antigen receptor T cell therapy","volume":"29","author":"Hubbeling","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2024092413262663100_bib32","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ijrobp.2022.07.491","article-title":"Patient-level disease burden as a predictor of in-field failures in patients undergoing bridging radiotherapy for CD19-directed chimeric antigen receptor (CAR) T-cell therapy for recurrent\/refractory large B-cell lymphomas","volume":"114","author":"Figura","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2024092413262663100_bib33","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.ijrobp.2021.07.297","article-title":"In-field failures in patients undergoing bridging radiotherapy for CD19-directed chimeric antigen receptor (CAR) T-cell therapy for recurrent\/refractory large B-cell lymphomas","volume":"111","author":"Sim","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2024092413262663100_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ajh.27155","article-title":"Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed\/refractory non-Hodgkin lymphoma: a multicenter consensus approach","volume":"99","author":"Saifi","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"2024092413262663100_bib35","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3324\/haematol.2022.281954","article-title":"Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response","volume":"108","author":"Jallouk","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2024092413262663100_bib36","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.ijrobp.2023.06.335","article-title":"Consolidative radiotherapy for residual PET-avid disease on day\u00a0+30 post CAR T-cell therapy in non-Hodgkin lymphoma","volume":"117","author":"Saifi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2024092413262663100_bib37","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.ijrobp.2022.07.436","article-title":"Comprehensive salvage radiotherapy for limited relapsed B-cell non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell therapy","volume":"114","author":"Saifi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4877\/2243809\/blooda_adv-2024-013647-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4877\/2243809\/blooda_adv-2024-013647-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:57:40Z","timestamp":1727186260000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4877\/517115\/Outcomes-of-patients-with-R-R-B-cell-NHL-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":37,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013647","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}